Skip to content
Screener
Q3 '26Q2 '26Q1 '26Q4 '25Q3 '25
$54.37M+326%$8.97M-61.3%$4.21M-95.0%$2.78M-95.4%$12.77M+38.5%
$45.36M+23.7%$47.96M+56.5%$44.07M+36.9%$41.98M+8.0%$36.68M+32.8%
$10.94M+20.7%$10.13M+25.2%$10.18M+16.9%$10.52M+19.8%$9.07M+11.5%
$56.31M+23.1%$58.1M+49.9%$54.24M+32.6%$52.5M+10.2%$45.74M+28.0%
-$1.94M+94.1%-$49.13M-216%-$50.03M-214%-$49.72M—-$32.98M-24.3%
-3.6%+255pp-547.8%-481pp-1,188.5%-1,240pp-1,787.7%—-258.3%+29.6pp
$5.63M+105%$5.92M+92.8%$5.59M+62.6%$3.69M+42.2%$2.75M-5.0%
$5.72M+110%$5.94M+33.3%$5.58M+52.1%$3.64M+40.1%$2.72M-0.8%
$3.78M+112%-$43.19M-289%-$44.45M-193%-$46.08M—-$30.26M-27.2%
$716K+123%$208K-82.7%$52K-93.7%$0-100%-$3.18M-4,575%
$3.06M+111%-$43.4M-253%-$44.5M-195%-$46.11M—-$27.08M-13.5%
5.6%+218pp-483.9%-431pp-1,057.1%-1,112pp-1,658%—-212.1%+46.8pp
$205K+101%-$47.22M-252%-$48.01M-204%-$47.63M—-$30.88M-26.4%
0.4%+242pp-526.5%-469pp-1,140.3%-1,195pp-1,712.6%—-241.9%+23.2pp
-$1.94M+94.1%-$49.13M-216%-$50.03M-214%-$49.72M—-$32.98M-24.3%

FAQ

What is Monte Rosa Therapeutics, Inc.'s revenue?
Monte Rosa Therapeutics, Inc. (GLUE) generated $70.3M in revenue over the trailing twelve months, down 61.3% year over year.
Is Monte Rosa Therapeutics, Inc. profitable?
Monte Rosa Therapeutics, Inc. is not currently profitable: it reported a net loss of $130.9M over the trailing twelve months, a -186.2% net margin.
What is Monte Rosa Therapeutics, Inc.'s earnings per share?
Monte Rosa Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-1.40.
Where does Monte Rosa Therapeutics, Inc.'s income statement data come from?
Every line is extracted from Monte Rosa Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.